vs
FEDERAL SIGNAL CORP（FSS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FEDERAL SIGNAL CORP的1.3倍（$772.1M vs $597.1M），Revvity净利率更高（12.7% vs 10.2%，领先2.6%），FEDERAL SIGNAL CORP同比增速更快（26.5% vs 5.9%），Revvity自由现金流更多（$161.8M vs $89.5M），过去两年FEDERAL SIGNAL CORP的营收复合增速更高（18.5% vs 9.0%）
联邦信号公司是20世纪早期的美国企业，主营铁路信号设备的制造业务，总部坐落于美国纽约州奥尔巴尼市，其生产的相关信号产品在当时的美国轨道交通行业得到了广泛应用，具备一定的行业知名度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FSS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$597.1M
营收增速更快
FSS
高出20.7%
5.9%
净利率更高
RVTY
高出2.6%
10.2%
自由现金流更多
RVTY
多$72.3M
$89.5M
两年增速更快
FSS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $597.1M | $772.1M |
| 净利润 | $60.8M | $98.4M |
| 毛利率 | 28.4% | — |
| 营业利润率 | 14.0% | 14.5% |
| 净利率 | 10.2% | 12.7% |
| 营收同比 | 26.5% | 5.9% |
| 净利润同比 | 21.6% | 3.9% |
| 每股收益（稀释后） | $0.99 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSSRVTY
| Q4 25 | $597.1M | $772.1M | ||
| Q3 25 | $555.0M | $698.9M | ||
| Q2 25 | $564.6M | $720.3M | ||
| Q1 25 | $463.8M | $664.8M | ||
| Q4 24 | $472.0M | $729.4M | ||
| Q3 24 | $474.2M | $684.0M | ||
| Q2 24 | $490.4M | $691.7M | ||
| Q1 24 | $424.9M | $649.9M |
净利润FSSRVTY
| Q4 25 | $60.8M | $98.4M | ||
| Q3 25 | $68.1M | $46.7M | ||
| Q2 25 | $71.4M | $53.9M | ||
| Q1 25 | $46.3M | $42.2M | ||
| Q4 24 | $50.0M | $94.6M | ||
| Q3 24 | $53.9M | $94.4M | ||
| Q2 24 | $60.8M | $55.4M | ||
| Q1 24 | $51.6M | $26.0M |
毛利率FSSRVTY
| Q4 25 | 28.4% | — | ||
| Q3 25 | 29.1% | 53.6% | ||
| Q2 25 | 30.0% | 54.5% | ||
| Q1 25 | 28.2% | 56.5% | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 29.6% | 56.3% | ||
| Q2 24 | 29.4% | 55.7% | ||
| Q1 24 | 27.3% | 54.6% |
营业利润率FSSRVTY
| Q4 25 | 14.0% | 14.5% | ||
| Q3 25 | 16.9% | 11.7% | ||
| Q2 25 | 17.3% | 12.6% | ||
| Q1 25 | 14.2% | 10.9% | ||
| Q4 24 | 14.9% | 16.3% | ||
| Q3 24 | 16.0% | 14.3% | ||
| Q2 24 | 16.5% | 12.4% | ||
| Q1 24 | 12.8% | 6.8% |
净利率FSSRVTY
| Q4 25 | 10.2% | 12.7% | ||
| Q3 25 | 12.3% | 6.7% | ||
| Q2 25 | 12.6% | 7.5% | ||
| Q1 25 | 10.0% | 6.4% | ||
| Q4 24 | 10.6% | 13.0% | ||
| Q3 24 | 11.4% | 13.8% | ||
| Q2 24 | 12.4% | 8.0% | ||
| Q1 24 | 12.1% | 4.0% |
每股收益（稀释后）FSSRVTY
| Q4 25 | $0.99 | $0.86 | ||
| Q3 25 | $1.11 | $0.40 | ||
| Q2 25 | $1.16 | $0.46 | ||
| Q1 25 | $0.75 | $0.35 | ||
| Q4 24 | $0.80 | $0.77 | ||
| Q3 24 | $0.87 | $0.77 | ||
| Q2 24 | $0.99 | $0.45 | ||
| Q1 24 | $0.84 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.7M | $919.9M |
| 总债务越低越好 | $564.6M | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.41× | — |
8季度趋势，按日历期对齐
现金及短期投资FSSRVTY
| Q4 25 | $63.7M | $919.9M | ||
| Q3 25 | $54.4M | $931.4M | ||
| Q2 25 | $64.7M | $991.8M | ||
| Q1 25 | $57.5M | $1.1B | ||
| Q4 24 | $91.1M | $1.2B | ||
| Q3 24 | $73.7M | $1.2B | ||
| Q2 24 | $48.6M | $2.0B | ||
| Q1 24 | $48.9M | $1.7B |
总债务FSSRVTY
| Q4 25 | $564.6M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $258.3M | — | ||
| Q1 25 | $266.9M | — | ||
| Q4 24 | $204.4M | — | ||
| Q3 24 | $223.3M | — | ||
| Q2 24 | $248.8M | — | ||
| Q1 24 | $266.8M | — |
股东权益FSSRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产FSSRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $1.8B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
负债/权益比FSSRVTY
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.17× | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $89.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.0% | 21.0% |
| 资本支出强度资本支出/营收 | 1.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $227.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FSSRVTY
| Q4 25 | $97.2M | $182.0M | ||
| Q3 25 | $61.1M | $138.5M | ||
| Q2 25 | $59.7M | $134.3M | ||
| Q1 25 | $36.7M | $128.2M | ||
| Q4 24 | $90.6M | $174.2M | ||
| Q3 24 | $68.8M | $147.9M | ||
| Q2 24 | $40.6M | $158.6M | ||
| Q1 24 | $31.3M | $147.6M |
自由现金流FSSRVTY
| Q4 25 | $89.5M | $161.8M | ||
| Q3 25 | $54.1M | $120.0M | ||
| Q2 25 | $52.4M | $115.5M | ||
| Q1 25 | $31.1M | $112.2M | ||
| Q4 24 | $82.1M | $149.8M | ||
| Q3 24 | $60.9M | $125.6M | ||
| Q2 24 | $24.8M | $136.6M | ||
| Q1 24 | $22.9M | $129.7M |
自由现金流率FSSRVTY
| Q4 25 | 15.0% | 21.0% | ||
| Q3 25 | 9.7% | 17.2% | ||
| Q2 25 | 9.3% | 16.0% | ||
| Q1 25 | 6.7% | 16.9% | ||
| Q4 24 | 17.4% | 20.5% | ||
| Q3 24 | 12.8% | 18.4% | ||
| Q2 24 | 5.1% | 19.7% | ||
| Q1 24 | 5.4% | 20.0% |
资本支出强度FSSRVTY
| Q4 25 | 1.3% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 1.8% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 3.2% | 3.2% | ||
| Q1 24 | 2.0% | 2.7% |
现金转化率FSSRVTY
| Q4 25 | 1.60× | 1.85× | ||
| Q3 25 | 0.90× | 2.97× | ||
| Q2 25 | 0.84× | 2.49× | ||
| Q1 25 | 0.79× | 3.03× | ||
| Q4 24 | 1.81× | 1.84× | ||
| Q3 24 | 1.28× | 1.57× | ||
| Q2 24 | 0.67× | 2.87× | ||
| Q1 24 | 0.61× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSS
| Vehiclesandequipment | $403.4M | 68% |
| Parts | $66.8M | 11% |
| Publicsafetyandsecurityequipment | $62.2M | 10% |
| Rentalincome | $19.0M | 3% |
| Industrialsignalingequipment | $18.2M | 3% |
| Other | $14.9M | 2% |
| Warningsystems | $12.6M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
